Commercial Insight: Transplantation

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-06-30

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

In 2005, over 50.000 solid organ transplants were conducted in the seven major markets. In order to prevent the patient's immune system from rejecting the transplanted organ, immunosuppression therapy is required for the lifetime of the graft with a base maintenance drug (either Calcineurin- or mTOR inhibitors) and adjunctive therapies (antimetabolites, steroids).


Scope

  • The report focuses on current and future therapies used for immunosuppression in solid organ transplantation, with sales and volume forecasts to 2015
  • Assessment of current and future dynamics, opportunities and threats for immunosuppressants across the seven major markets
  • Overview of organ supply, national donation rates, waiting lists and forecasts of the number of transplants and maintenance population to 2015
  • Assessment of key factors affecting prescription choice, including analysis of regional differences


    • Report Highlights
    The transplantation market poses unusual challenges to pharmaceutical companies, the most significant one being a lack of donor organs: the waiting list for transplants will continue to grow faster than the number of available organs. Another challenge is the static nature of the market: maintenance regimens of stable patients rarely get changed.

    The market for immusuppresssants used in transplantation is set to grow to $4.3 billion by 2015s. Despite changing protocols, the leading drug class by value should continue to be calcineurin inhibitors with a 37% market share, followed by mTOR inhibitors.

    mTOR inhibitors are expected to be the fastest growing class, driven by Wyeth's Rapamune. Datamonitor foresees the drug to gain a greater role as a primary immunsuppressant despite current tolerability issues. Bristol Myers Squibb's injectable fusion protein belatacept may offer another alternative to calcineurin inhibitors


    Reasons to Purchase

  • Identify and understand the dynamics in immunosuppressive protocols as reflected in opinion leaders' thoughts
  • Quantify the future immunosuppressant market size by volume and value for each of the seven major markets
  • Quantify the future market size based on transplant types, numbers and the maintenance population

    • Table of Contents

    Other users found this report page using the following search terms: tranplantation organ transplant patent market cellcept generic prograf expiry tacrolimus sales belatacept transplant

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.